Overview |
bsm-54163R |
LOXL2 (7D7) Monoclonal Antibody |
WB, FCM, IHC-P, IF(IHC-P), IF(ICC) |
Human, Mouse, Rat |
Specifications |
Unconjugated |
Rabbit |
Synthetic peptide within Human LOXL2 aa 750 to the C-terminus |
Monoclonal |
7D7 |
IgG |
1ug/ul |
Purified by Protein A. |
Aqueous buffered solution containing 1xTBS (pH7.4), 1%BSA, 40%Glycerol and 0.05% Sodium Azide. |
Store at 4C for up to 2 weeks. For long term storage, store at -20C in small aliquots to prevent freeze-thaw cycles. |
Target |
4017 |
Q9Y4K0 |
Nucleus, Secreted, Endoplasmic reticulum |
Lysyl oxidase homolog 2; Lysyl oxidase-like protein 2; Lysyl oxidase-related protein 2; Lysyl oxidase-related protein WS9-14; LOXL2; |
Mediates the post-translational oxidative deamination of lysine residues on target proteins leading to the formation of deaminated lysine (allysine). When secreted in the extracellular matrix, promotes cross-linking of extracellular matrix proteins by mediating oxidative deamination of peptidyl lysine residues in precursors to fibrous collagen and elastin. Acts as a regulator of sprouting angiogenesis, probably via collagen IV scaffolding. When nuclear, acts as a transcription corepressor and specifically mediates deamination of trimethylated 'Lys-4' of histone H3 (H3K4me3), a specific tag for epigenetic transcriptional activation. Involved in epithelial to mesenchymal transition (EMT) via interaction with SNAI1 and participates in repression of E-cadherin, probably by mediating deamination of histone H3. Also involved in E-cadherin repression following hypoxia, a hallmark of epithelial to mesenchymal transition believed to amplify tumor aggressiveness, suggesting that it may play a role in tumor progression. Acts as a regulator of chondrocyte differentiation, probably by regulating the expression of factors that control chondrocyte differentiation. |
Application Dilution |
WB |
1:300-5000 |
FCM |
1:20-100 |
IHC-P |
1:200-400 |
IF(IHC-P) |
1:50-200 |
IF(ICC) |
1:50-200 |